Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Predictive models of immune protection from COVID-19 are urgently needed to identify
correlates of protection to assist in the future deployment of vaccines. To address this, we …
correlates of protection to assist in the future deployment of vaccines. To address this, we …
[HTML][HTML] Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection
and vaccine development. Here, we show a comprehensive profile of antibody, B cell …
and vaccine development. Here, we show a comprehensive profile of antibody, B cell …
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Background Several SARS-CoV-2 variants of concern have been identified that partly escape
serum neutralisation elicited by current vaccines. Studies have also shown that vaccines …
serum neutralisation elicited by current vaccines. Studies have also shown that vaccines …
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data …
2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data …
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement. …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement. …
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
…, HG Kelly, K Wragg, R Esterbauer, HE Kent… - Nature medicine, 2020 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
dramatically expedited global vaccine development efforts 1 , 2 – 3 , most targeting the viral ‘spike’ …
dramatically expedited global vaccine development efforts 1 , 2 – 3 , most targeting the viral ‘spike’ …
Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and …
SJ Kent, A Zhao, SJ Best, JD Chandler… - Journal of …, 1998 - Am Soc Microbiol
The induction of human immunodeficiency virus (HIV)-specific T-cell responses is widely
seen as critical to the development of effective immunity to HIV type 1 (HIV-1). Plasmid DNA …
seen as critical to the development of effective immunity to HIV type 1 (HIV-1). Plasmid DNA …
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing knowledge …
central to long-term control of the current pandemic. Despite our rapidly advancing knowledge …
Tuberculous meningitis: a 30-year review
SJ Kent, SM Crowe, A Yung, CR Lucas… - Clinical infectious …, 1993 - academic.oup.com
Tuberculous meningitis remains an important illness that can be difficult to diagnose in a
timely fashion and carries significant morbidity. We present a retrospective review of the cases …
timely fashion and carries significant morbidity. We present a retrospective review of the cases …
